Announced Sat, 7 Feb · 15:30 IST

Outcome of Board Meeting held on 07th February, 2026.

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The board of Symbiox Investment & Trading Company met on 7th February 2026 and approved the unaudited financial results for the quarter ended 31st December 2025 (Q3 FY26). Revenue from operations for the quarter stood at ₹8.60 lakh, a sharp drop from ₹45.47 lakh in the same quarter last year. Net profit for the quarter fell to ₹1.23 lakh versus ₹15.85 lakh in Q3 FY25. For the nine months ended December 2025, net profit was ₹14.01 lakh compared to ₹49.13 lakh a year earlier, a decline of about 71%. The statutory auditor SS RV & Associates issued an unqualified limited review report, noting no material misstatements. EPS for Q3 FY26 came in at just ₹0.004 per share.

Likely market impact

Sharp year-on-year decline in both revenue and profit signals weaker trading/investment activity and is a negative signal for shareholders. The very low absolute earnings and small scale of operations make this stock highly volatile and sensitive to any single quarter's performance.